Medicaid

First Opinion By Eric Letsinger and Alison Rein

Invest in community-based organizations to put health dollars where they are really needed

STAT+ Conversations By Casey Ross

‘I can’t imagine going back’: Medicare leader calls for expanded telehealth access after Covid-19

Pharmalot By Ed Silverman

Mallinckrodt loses a court case and is on the hook for $650 million in overdue Medicaid rebates

First Opinion By Eric Schneider

Super Tuesday results suggest that Americans ‘aren’t looking for big structural changes’ in health care

Pharmalot By Ed Silverman

PBMs favor their own pharmacies in the Florida Medicaid program

Pharmalot By Ed Silverman

U.S. officials will let Novartis pay expenses for some Kymriah patients who must travel for treatment

First Opinion By Ira Byock and Eric Walsh

Hopewell House hospice has closed. You should care about that

Politics By Priyanka Dayal McCluskey — Boston Globe and Matt Stout — Boston Globe

Mass. governor — and one-time insurance executive — eyes a legacy-defining revamp of state’s health care

Pharmalot By Ed Silverman

Pharmalittle: Five companies offer $50 billion deal to settle opioid suits; FDA approves record number of generics

Pharmalot By Ed Silverman

Most state Medicaid programs continue to restrict access to hepatitis C medicines

Pharmalot By Ed Silverman

A murky approach to tracking 340B drugs and Medicaid may yield double discounts in some states

Pharmalot By Ed Silverman

Avanir to pay $116 million to settle bribery charges, while two docs and former sales reps are indicted

Pharmalot By Ed Silverman

Mylan pays $30 million to settle charges of misleading investors over probe into EpiPen Medicaid rebates

Pharmalot By Ed Silverman

Few Americans took obesity drugs thanks to doctor doubts and spotty insurance

First Opinion By Chuck Grassley

Grassley: For Medicaid, greater transparency will open the door to better value and outcomes

Pharmalot By Ed Silverman

Massachusetts lawmakers approve compromise bill to lower Medicaid drug spending

Pharmalot By Ed Silverman

Pharmalittle: Trump abandons rebate rule; biotechs fume at Mass. governor’s plan to lower drug prices

Pharmalot By Ed Silverman

Reckitt will pay $1.4 billion to settle federal probes into marketing of opioid-addiction treatment

Health By Ruth Hailu

‘Sickle cell needs more funding’: An 18-year-old patient advocate calls on Washington to improve children’s health care

Business By Jonathan Saltzman — Boston Globe

Drug-pricing watchdog group is ‘mouse that roared’

Pharmalot By Ed Silverman

Pharmalittle: Pfizer to buy Array for $11 billion, Teva settlement in Oklahoma may hit a new snag

Health Tech By Megan Thielking

5 names to know at Uber and Lyft: the key players behind ride-sharing’s move into health care

Pharmalot By Ed Silverman

Pharmalittle: Lawmakers push bill to punish opioid execs; Novartis will have ‘enormous leverage’ pricing its SMA drug

Pharmalot By Ed Silverman

Mallinckrodt sues CMS over Medicaid rebates for its pricey Acthar Gel medicine

Pharmalot By Ed Silverman

Seeking to contain drug costs, CMS may have ‘killed’ a PBM billing practice